Atrial fibrillation is the most common heart-rhythm disorder in adults, and people with chronic kidney disease carry a particularly high burden of it. The two conditions feed each other: impaired kidney function raises inflammation and fluid imbalances that stress the heart, while an irregular heartbeat reduces the blood flow kidneys need to stay healthy. Researchers have long looked for therapies that could address both problems at once.
GLP-1 receptor agonists are a class of peptides that mimic glucagon-like peptide 1, a hormone the gut releases after eating. They are best known for their role in blood-sugar regulation and body-weight research, but a growing body of evidence points toward broader effects on the heart and kidneys. A recent retrospective cohort study published in Cardiovascular Drugs and Therapy set out to ask a focused question: are patients with chronic kidney disease who use GLP-1 receptor agonists less likely to develop atrial fibrillation than those who do not?
Study design and patient population
The research team drew on the TriNetX US Collaborative Network, a large database of real-world electronic health records. They identified patients who had a diagnosis of chronic kidney disease but had not yet experienced atrial fibrillation or progressed to kidney failure requiring dialysis. The first prescription for a GLP-1 receptor agonist served as the starting point for the treated group. For patients who never used the peptide, a comparable outpatient visit after their kidney-disease diagnosis served as an equivalent anchor date.
To make the two groups as comparable as possible, the investigators used a statistical technique called propensity score matching. This approach pairs each treated patient with a non-treated patient who looks almost identical on a long list of baseline characteristics, including age, sex, race, diabetes status, obesity, blood pressure, and kidney function. After matching, each group contained 37,768 patients. The average age was 67 years, roughly 55 percent were female, 21 percent were Black, 63 percent had diabetes, and the average body mass index was around 34. Average kidney filtration rate, measured as eGFR, was 49 milliliters per minute, which places most participants in the moderate-to-moderately-severe range of chronic kidney disease.
Patients were then followed for up to three years, until death, or until the study period ended. The primary outcome the researchers tracked was new-onset atrial fibrillation.
Main findings on atrial fibrillation
Over the follow-up period, 6.9 percent of patients in the GLP-1 receptor agonist group developed atrial fibrillation, compared with 12.4 percent in the non-user group. In survival analysis terms, that translated to a hazard ratio of 0.59, with a 95 percent confidence interval of 0.56 to 0.62. Put plainly, the literature suggests that GLP-1 receptor agonist use was associated with roughly 41 percent lower relative risk of a new atrial fibrillation diagnosis over three years.
What makes these findings especially notable is that the association held up in subgroups defined by the absence of the conditions these peptides are most commonly studied in. Among patients who were not obese, the hazard ratio was 0.63. Among patients who did not have diabetes, it was 0.42. Among patients who had neither diabetes nor obesity, the hazard ratio was 0.59. These consistent results across subgroups suggest the observed association is not simply a byproduct of weight loss or blood-sugar control, though the study design cannot establish causation.
Secondary cardiovascular and kidney outcomes
Beyond the primary atrial fibrillation finding, the study tracked a range of secondary outcomes. GLP-1 receptor agonist use was associated with lower rates of AF-related interventions, a composite category that included procedures such as ablation, cardioversion, left atrial appendage occlusion, and pacemaker implantation, with a hazard ratio of 0.58.
Heart failure exacerbation showed one of the more striking associations in the dataset, with a hazard ratio of 0.48, meaning roughly half the rate in the treated group compared with matched controls. Use of antiarrhythmic medications, a proxy for how much clinical management was needed to control heart rhythm, was also lower, with a hazard ratio of 0.60. Major adverse cardiovascular events as a composite came in at a hazard ratio of 0.58.
On the kidney side, progression to kidney failure requiring dialysis carried a hazard ratio of 0.70, and major adverse kidney events as a broader composite reached a hazard ratio of 0.55. All-cause death showed a hazard ratio of 0.52, meaning the GLP-1 receptor agonist group had roughly half the mortality rate of the matched controls over the observation window.
Possible biological mechanisms
The study was observational, so the researchers did not measure the biological pathways involved. However, the existing scientific literature offers several plausible mechanisms worth understanding.
GLP-1 receptors are found not only in pancreatic tissue but also in the heart, including in the sinoatrial node and atrial tissue itself. Activation of these receptors has been linked in animal and cellular studies to reduced oxidative stress and inflammation in cardiac tissue, both of which are known contributors to atrial remodeling, the structural changes that make atrial fibrillation more likely to occur and persist.
Chronic kidney disease is associated with chronic low-grade inflammation, fluid retention, and activation of the renin-angiotensin-aldosterone system, all of which place mechanical and biochemical stress on the atria. If GLP-1 receptor agonists reduce systemic inflammation and improve sodium and fluid handling at the kidney level, as some mechanistic research suggests, they might indirectly reduce the substrate that allows atrial fibrillation to develop.
Weight reduction, when it occurs, may contribute separately, since excess body weight is an independent risk factor for atrial fibrillation. The non-obese and non-diabetic subgroup analyses in this study suggest that weight and glucose effects do not fully explain the association, but they cannot rule out a partial contribution.
Limitations and research context
The authors acknowledged several important limitations that a careful reader should weigh. The study was retrospective, meaning it analyzed data that were already collected for other purposes rather than being prospectively designed to test this hypothesis. That limits the ability to infer causation rather than association.
Real-world database studies also carry the risk of residual confounding. Even after propensity score matching, unmeasured differences between groups, such as motivation to adhere to other health behaviors, could influence results. Atrial fibrillation is also notoriously underdiagnosed, since many episodes are silent and only detected through routine monitoring or wearable devices, which patients in the treated group may have been more likely to use.
The study did not distinguish between individual GLP-1 receptor agonists within the class, which may have different potency and tissue-selectivity profiles. Future prospective trials would be needed to confirm these associations and to clarify whether specific agents within the class drive the effect or whether it is a class-wide property.
Despite these limitations, the scale of the matched cohort, nearly 76,000 patients in total, and the consistency of findings across multiple subgroups and outcomes give the results meaningful weight in the research literature.
What this means for the research landscape
This study adds to an accumulating picture of GLP-1 receptor agonists as peptides with cardiovascular effects that extend well beyond their original metabolic applications. Earlier cardiovascular outcome trials demonstrated reductions in major adverse cardiovascular events in people with diabetes and established heart disease. Dedicated kidney outcome trials have shown slowing of CKD progression. This retrospective cohort analysis now adds atrial fibrillation to the list of outcomes where an association has been observed.
For researchers and clinicians interested in the cardiorenal intersection, the non-diabetic and non-obese subgroup findings are probably the most scientifically interesting thread to pull. They raise the possibility that GLP-1 receptor signaling has direct cardiac electrophysiological relevance independent of metabolic state. Prospective trials focused specifically on atrial fibrillation endpoints in CKD populations would be needed to move from association to a more confident mechanistic understanding.
